{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=13+valent+Pneumococcal+Conjugate+Vaccine",
    "query": {
      "intervention": "13 valent Pneumococcal Conjugate Vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 93,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=13+valent+Pneumococcal+Conjugate+Vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T16:46:08.497Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01978093",
      "title": "Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neisseria Meningitidis",
        "Haemophilus Influenzae Type b"
      ],
      "interventions": [
        {
          "name": "Hib-MenCY-TT (MenHibrix®)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PedvaxHIB®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 600,
      "start_date": "2014-02-01",
      "completion_date": "2016-03-18",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01978093"
    },
    {
      "nct_id": "NCT03039491",
      "title": "Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "HIV Lipodystrophy",
        "Aging"
      ],
      "interventions": [
        {
          "name": "Pneumococcal polysaccharide vaccine 23 valent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13 valent conjugated pneumococcal vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 160,
      "start_date": "2015-09-01",
      "completion_date": "2020-03-30",
      "has_results": false,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03039491"
    },
    {
      "nct_id": "NCT00980655",
      "title": "Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vaccines, Pneumococcal Conjugate Vaccine"
      ],
      "interventions": [
        {
          "name": "13vPnC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "23vPS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 251,
      "start_date": "2010-01-18",
      "completion_date": "2013-05-16",
      "has_results": true,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 9,
      "location_summary": "Lexington, Kentucky • New Hyde Park, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00980655"
    },
    {
      "nct_id": "NCT03893448",
      "title": "Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections",
        "Pneumococcal Vaccines"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RotaTeq™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pentacel™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RECOMBIVAX HB™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAQTA™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR II™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VARIVAX™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HIBERIX™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "90 Days",
        "sex": "ALL",
        "summary": "42 Days to 90 Days"
      },
      "enrollment_count": 1720,
      "start_date": "2019-06-19",
      "completion_date": "2021-05-24",
      "has_results": true,
      "last_update_posted_date": "2023-07-28",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Opp",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893448"
    },
    {
      "nct_id": "NCT03731182",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 104,
      "start_date": "2019-01-23",
      "completion_date": "2020-06-08",
      "has_results": true,
      "last_update_posted_date": "2021-06-16",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 6,
      "location_summary": "Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03731182"
    },
    {
      "nct_id": "NCT02518555",
      "title": "Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jennifer Woyach",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2016-01-12",
      "completion_date": "2026-01-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02518555"
    },
    {
      "nct_id": "NCT01128426",
      "title": "Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pneumococcal Disease"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "2 Months to 3 Years"
      },
      "enrollment_count": 53902,
      "start_date": "2010-06",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-07-14",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01128426"
    },
    {
      "nct_id": "NCT01527591",
      "title": "Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infection in Solid Organ Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "Pneumococcal Conjugate Vaccine 13 (PCV13)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "12 Months to 59 Months"
      },
      "enrollment_count": 17,
      "start_date": "2012-02-01",
      "completion_date": "2025-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01527591"
    },
    {
      "nct_id": "NCT03942328",
      "title": "Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage III Hepatocellular Carcinoma AJCC v8",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v8",
        "Stage IV Hepatocellular Carcinoma AJCC v8",
        "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8",
        "Unresectable Hepatocellular Carcinoma",
        "Unresectable Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Therapeutic Autologous Dendritic Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Esophagogastroduodenoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2019-09-19",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03942328"
    },
    {
      "nct_id": "NCT04080531",
      "title": "Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2019-10-18",
      "completion_date": "2022-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-09-29T16:46:08.497Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04080531"
    }
  ]
}